Literature DB >> 15448171

Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.

Young-Joo Lee1, Hiroyuki Kusuhara, Johan W Jonker, Alfred H Schinkel, Yuichi Sugiyama.   

Abstract

Breast cancer resistance protein (Bcrp/Abcg2) is a new efflux transporter found at the blood-brain barrier (BBB) of humans and pigs. Since it has been hypothesized that Bcrp may act as a new type of efflux transporter at the BBB, we investigated the involvement of Bcrp in the efflux transport of typical substrates, dehydroepiandrosterone sulfate (DHEAS) and mitoxantrone, across the mouse BBB. The expression of Bcrp in mouse brain capillaries was confirmed by quantitative polymerase chain reaction, Western blot, and immunohistochemical analysis. The role of Bcrp as an efflux transporter was evaluated using the in situ brain perfusion method in wild-type and P-glycoprotein (P-gp) knockout mice with or without treatment with GF120918 (Elacridar), an inhibitor of both Bcrp and P-gp. The increased brain uptake of [(3)H]DHEAS and [(3)H]mitoxantrone by GF120918 in wild-type and P-gp knockout mice suggested the existence of a GF120918-sensitive and P-gp-independent efflux transporter for DHEAS and mitoxantrone across the BBB. However, the brain uptake of [(3)H]DHEAS in Bcrp knockout mice was comparable with that in wild-type mice, and the effect of GF120918 was still observed in Bcrp knockout mice. In addition, the brain uptake of [(3)H]mitoxantrone was also similar in wild-type and Bcrp knockout mice. These results suggest that although BCRP is expressed at the BBB it plays a minor role in active efflux transport of DHEAS and mitoxantrone out of brain and that one or more GF120918-sensitive efflux transporters distinct from BCRP or P-gp contributes to the brain efflux of DHEAS and mitoxantrone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448171     DOI: 10.1124/jpet.104.073320

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

Review 1.  In vivo methods to study uptake of nanoparticles into the brain.

Authors:  Inge van Rooy; Serpil Cakir-Tascioglu; Wim E Hennink; Gert Storm; Raymond M Schiffelers; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2010-10-07       Impact factor: 4.200

2.  Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.

Authors:  Sagar Agarwal; Yasuo Uchida; Rajendar K Mittapalli; Ramola Sane; Tetsuya Terasaki; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2012-03-08       Impact factor: 3.922

Review 3.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 4.  ATP-binding cassette, subfamily G (ABCG family).

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

Review 5.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 6.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 7.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.

Authors:  Sagar Agarwal; Ramola Sane; Rajneet Oberoi; John R Ohlfest; William F Elmquist
Journal:  Expert Rev Mol Med       Date:  2011-05-13       Impact factor: 5.600

Review 8.  Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies.

Authors:  Ranjeet Prasad Dash; R Jayachandra Babu; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

9.  Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.

Authors:  Birk Poller; Jürgen Drewe; Stephan Krähenbühl; Jörg Huwyler; Heike Gutmann
Journal:  Cell Mol Neurobiol       Date:  2009-07-23       Impact factor: 5.046

10.  Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.

Authors:  Rong Zhao; Thomas J Raub; Geri A Sawada; Steven C Kasper; James A Bacon; Arlene S Bridges; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2009-03-09       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.